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Homozygous Mutations in TBC1D23 Lead
to a Non-degenerative Form
of Pontocerebellar Hypoplasia
Isaac Marin-Valencia,1 Andreas Gerondopoulos,2 Maha S. Zaki,3 Tawfeg Ben-Omran,4
Mariam Almureikhi,4 Ercan Demir,5 Alicia Guemez-Gamboa,1 Anne Gregor,1 Mahmoud Y. Issa,3
Bart Appelhof,6 Susanne Roosing,1 Damir Musaev,7 Basak Rosti,1,7 Sara Wirth,7 Valentina Stanley,7
Frank Baas,6 Francis A. Barr,2 and Joseph G. Gleeson1,7,*
Pontocerebellar hypoplasia (PCH) represents a group of recessive developmental disorders characterized by impaired growth of the pons
and cerebellum, which frequently follows a degenerative course. Currently, there are 10 partially overlapping clinical subtypes and 13
genes knownmutated in PCH. Here, we report biallelic TBC1D23mutations in six individuals from four unrelated families manifesting a
non-degenerative form of PCH. In addition to reduced volume of pons and cerebellum, affected individuals had microcephaly, psycho-
motor delay, and ataxia. In zebrafish, tbc1d23 morphants replicated the human phenotype showing hindbrain volume loss. TBC1D23
localized at the trans-Golgi and was regulated by the small GTPases Arl1 and Arl8, suggesting a role in trans-Golgi membrane trafficking.
Altogether, this study provides a causative link between TBC1D23 mutations and PCH and suggests a less severe clinical course than
other PCH subtypes.
Originally named by Brun in 1917,1 pontocerebellar hypo-
plasia (PCH) is a devastating neurological disorder charac-
terized by impaired growth and/or degeneration of cerebral
structures, primarily the pons and cerebellum. To date, ten
different clinical subtypes of PCH have been described, the
majority leading to a neurodegenerative course, manifest-
ing with progressive intellectual and motor decline.2,3
Treatments are only palliative and the prognosis is poor,
as most affected individuals die during infancy or child-
hood. Despite the expansion of known genes associated
with PCH, most individuals remain without genetic diag-
nosis, suggesting that additional causes remain to be
identified.
We recruited a cohort of 75 families with likely auto-
somal-recessive PCH, of which 53 (70.6%) documented
parental consanguinity and 19 (25.3%) had two or more
affected individuals. All affected members were clinically
evaluated by a pediatric neurologist and geneticist, blood
and/or saliva samples and skin biopsies were collected
from participating individuals after obtaining proper
informed consent, and DNA for whole-exome sequencing
(WES) was extracted from at least one affected member of
each family as described.4 The study followed the IRB
guidelines and was approved by the ethical committees
of UC San Diego, The Rockefeller University, and other
participating institutions. In consanguineous families, we
emphasized homozygous, rare (<0.1% allele frequency in
our exome database of 5,000 individuals), and potentially
damaging variants (Genomic Evolutionary Rate Profile
[GERP] score > 4 or phastCons > 0.9).5 Likely causative
mutations were identified in 47 families (62.6% of the to-
tal) (Figure 1A). Seven families (9.3%) had a likely causative
variant in a gene not previously implicated in PCH. A total
of 34 families (45.3%) carried mutations in genes previ-
ously associated with degenerative forms of PCH, encoding
proteins involved in tRNA splicing, mRNA processing, and
protein synthesis.5–8 Six families (8%) demonstrated a
non-degenerative course of PCH, and among these,
TBC1D23mutations were identified as a cause for this con-
dition. TBC1D23 has been recently linked also with auto-
somal-recessive intellectual disability.9 We found six
affected individuals with mutations in TBC1D23 from
four unrelated families from Egypt (families I and II),
Turkey (family III), and Lebanon (family IV) (Figures 1B
and S1).
Family I presented with two affected boys of 16 years
(I-IV-1) and 2 years (I-IV-5) of age, family II presented
with two non-identical girl twins of 4 years of age (II-III-1
and II-III-2), family III presented with one boy of
14 months of age (III-IV-1), and family IV presented with
a girl of 6 months of age (IV-II-1) (Figure 1B). Some of these
individuals manifested reduced head circumference at
birth (R2 SD standard deviations [SD] below the mean)
and all showed signs of global psychomotor deficits since
early infancy, involving gross and fine motor skills, lan-
guage (expressive > receptive), and social interaction due
to communication impairment (Table 1). In the most
recent clinical evaluation, all subjects were microcephalic
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(R3 SD), and height and weight ranged from normal
to 5 SD. Neurological exam was remarkable for general-
ized weakness (6/6 affected subjects), global hypotonia
(5/6), and cerebellar deficits such as uncoordinated limb
movements (4/6), hyporeflexia (3/6), and impaired or
no ambulation (6/6). Brainstem symptoms including
dysphagia and dysarthria were present in subjects from
family I. None of the six individuals manifested clinical
signs of neurological deterioration and, hitherto, they are
all alive. Brain MRI showed pontocerebellar hypoplasia
in all subjects, along with thin corpus callosum (I-IV-5,
II-III-1, II-III-2, IV-II-1) and cortical hypoplasia (I-IV-5,
II-III-1, II-III-2) (Figure 1C). The radiological findings of
subject III-IV-1 did not change appreciably over a 3-year in-
terval (Figure S2), which is consistent with the non-pro-
gressive course of this form of PCH.
All six affected individuals carried mutations predicted
to result in altered splicing, occurring at or near canonical
splice sites (Figure 1D; Table 1), so we used genome build
hg19 and transcript GenBank: NM_001199198.2 (tran-
script 1) to annotate splicing effects. We found that both
TBC1D23 transcripts were differently expressed in human
tissues, with transcript 1 primarily expressed in the fetal
and adult brain and spinal cord (Figure 2A). To study po-
tential effects of the variants on splicing, we used RT-PCR
to amplify annotated transcripts from fibroblasts of fam-
ilies II and III, who carried mutations c.1687þ2T>A and
c.1687þ1G>A, respectively (primers are available upon
A B
C
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Figure 1. Homozygous Mutations in TBC1D23 Lead to Pontocerebellar Hypoplasia
(A) Summary of exome sequencing results from a cohort of 75 families with pontocerebellar hypoplasia. Most PCH subtypes showed
neurodegenerative features and the genes found in this group were primarily associated with RNA processing (TSEN54, TSEN2, TOE1,
and CLP1) and with metabolism (AMPD2). In the non-degenerative group, TBC1D23 was the most frequent gene, accounting for
5.3% of families, and VLDLR was found in 2.6% of the families.
(B) Pedigrees showing consanguinity in three families. A total of six affected subjects were identifiedwith different deleteriousmutations
in TBC1D23. Mutation in brackets has a presumed effect on splicing.
(C) Available midline sagittal T1-weighed MRIs and facies from affected individuals are shown. All individuals manifested severe hypo-
plasia of pons (red arrow) and moderate to severe hypoplasia of the cerebellum (orange arrow) and all but III-IV-1 had hypoplasia
of corpus callosum (yellow arrow). All were microcephalic and none of them showed obvious signs of facial dysmorphism. Subject
II-III-2 had head deviation due to neck hypotonia.
(D) TBC1D23 exons as ticks and location of mutations are indicated in both transcripts. A schematic of the protein structure is illustrated
along with the protein mutation of families II and III.
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Table 1. Description of Clinical Findings of Individuals with TBC1D23 Mutations
I-IV-1 I-IV-5 II-III-1 II-III-2 III-VI-1 IV-II-1
Mutation (genomic hg19) chr3:g.100029386G>A chr3:g.100029386G>A chr3:g.100035033T>A chr3:g.100035033T>A chr3:g.100035032G>A chr3:g.100014144A>G
Mutation (cDNA) (NM_001199198.2) c.1553G>A c.1553G>A c.1687þ2T>A c.1687þ2T>A c.1687þ1G>A c.7262A>G
Mutation (protein) p.[Arg518Gln;?] p.[Arg518Gln;?] p.His534Trpfs*36 p.His534Trpfs*36 p.His534Trpfs*36 p.?
Gestational age 40 38 37 37 N/A N/A
Weight at birth (kg) 3 (0.90 SD) 2.8 (1.22 SD) 1.6 (3.47 SD) 1.5 (3.66 SD) 3.8 (þ0.49 SD) 8.8 at age 2 years (3 SD)
Length at birth (cm) 50 (0.06 SD) 48 (0.81 SD) 48 (0.65 SD) 47 (1.10 SD) N/A N/A
HC at birth (cm) 32.2 (1.62 SD) 32 (1.71 SD) 32 (1.90 SD) 31.5 (2.24 SD) 42 at 14 months
(3.84 SD)
41.2 at 2 years (4.4 SD)
Age at diagnosis delayed since infancy, but
first seen at 16 years of age
2 years delayed since infancy, but
first seen at 4 years of age
delayed since infancy, but
first seen at 4 years of age
14 months 6 months
Weight (kg), age at last examination 38, 16 years (2.65 SD) 14, 6 years (2.96 SD) 14.5, 4 years (0.79 SD) 11.5, 4 years (2.62 SD) N/A 11.9, 7.5 years (4.11 SD)
Height (cm), age at last examination 143, 16 years (3.56 SD) 103, 6 years (2.44 SD) 103, 4 years (þ0.50 SD) 97, 4 years (0.89 SD) N/A 98, 7.5 years (4.89 SD)
HC (cm), age at last examination 48, 16 years (4.77 SD) 44.5, 6 years (5.27 SD) 43.5, 4 years (3.96 SD) 41.5, 4 years (5.25 SD) 50, 16 years (3.4 SD) 42, 7.5 years (7.77 SD)
Psychomotor Development
Gross motor delayed; can walk alone delayed; sits only delayed; can walk alone delayed; walks supported delayed delayed
Fine motor delayed delayed delayed delayed absent delayed
Language delayed delayed delayed delayed absent delayed (babbling at
7 years of age)
Social delayed delayed delayed delayed absent delayed
Regression of acquired milestones – – – – – –
Neurological Findings
Brainstem findings dysarthria. no history of
apnea, hearing deficit,
dizziness, or dysphagia
minimal dysphagia.
no history of apnea,
hearing deficit, or
dizziness.
– – N/A –
Cerebellar deficits truncal and
appendicular ataxia
truncal and
appendicular ataxia
truncal and appendicular
ataxia
truncal and appendicular
ataxia
– –
Muscle strength (scale 0->5 in
upper and lower extremities)
grade 4/5 grade 4/5 grade 4/5 grade 4/5 grade 5/5 grade 3/5
Muscle tone hypotonia hypotonia hypotonia hypotonia normal muscle tone hypotonia; reduced
muscle tone at 2 years,
but developed spasticity
especially in lower
limbs at 7 years.
(Continued on next page)
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request). Affected individuals had shorter transcripts rela-
tive to control individuals (Figure 2B), and sequencing
of the amplified PCR products confirmed that shorter
transcripts had skipped exon 16 (Figure 2C), leading to
a shift in the reading frame and truncated protein
(p.His534Trpfs*36) (Figures 1D and 2D). Fibroblasts from
families I and IV were not available to assess splicing.
Family IV carried a variant in a canonical splice site
(c.7262A>G) and family I carried a missense mutation
at the last base of exon 14 (c.1553G>A), both of which
were also expected to compromise splicing. Cellular local-
ization of endogenous TBC1D23 was examined in control,
carrier, and affected individuals’ fibroblasts using specific
antibodies. In control fibroblasts, TBC1D23 overlapped
with the trans-Golgi marker TGN46 and showed signal
adjacent to the cis-Golgi marker GM130 (Figure 2E). This
trans-Golgi staining pattern of TBC1D23 was absent in
cells from affected individuals, whereas cells from carriers
showed reduced staining intensity. Despite the loss of
detectable TBC1D23 in affected subjects (Figures 2D and
2E), there was no obvious alteration in the relative posi-
tions of the cis/trans-Golgi markers or the ribbon-like struc-
ture of the Golgi (Figure 2E).
TBC1D23 belongs to a family of Tre2-Bub2-Cdc16
(TBC) domain-containing Rab-specific GTPase-activating
proteins (TBC/RabGAPs) that regulate membrane traf-
ficking by inactivating Rabs.10–12 Most TBC/RabGAPs
contain two catalytic residues, Arg and Gln, to stimulate
the hydrolysis of GTP in Rab proteins.13,14 TBC1D23 falls
in the category of unconventional TBC/RabGAPs since it
lacks the catalytic Arg-Gln residues and it might, a priori,
work through a different mechanism to induce GTP hydro-
lysis14 or it might have a Rab-independent function.When
compared to TBC1D20, which acts on Rab1, none of the 55
Rabs tested showed robust activation of GTP hydrolysis in
the presence of purified TBC1D2315 (Figure S3). This raised
the possibility that TBC1D23 is a Rab-binding protein, or
effector, rather than a Rab regulator and it may target to
the Golgi via this means. However, two lines of evidence
argue against this. First, a region in TBC1D23 (469–570
aa), C-terminal to the TBC1 and Rhodanese domains, is
responsible for its targeting to the trans-Golgi (Figures 3A
and 3B). Second, TBC1D23 remains associated with trans-
Golgi membranes when Rabs are depleted, with just a sub-
set (Rab1a/b, Rab2a/b, Rab6a/b, Rab7a, Rab14a/b) giving
rise to altered TBC1D23 localization due to their effects
on Golgi structure or trafficking to and from the Golgi
(Figure S3). This suggested a Rab-independent targeting
mechanism.
Like Rabs, Ras superfamily GTPases of the Arl and Arf
group are known to be involved in recruitment of cytosolic
proteins to membrane surfaces. Strikingly, depletion of
Arl1, but not ArfRP1 or other Arfs or Arls, resulted in
the complete loss of TBC1D23 from the trans-Golgi
(Figure 3C). Conversely, knocking down Arl8 resulted
in elevated staining for TBC1D23 at the trans-Golgi
(Figure 3C). These findings connect TBC1D23 to anTa
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Arl1-dependent trafficking process at the trans-Golgi16–19
and to Arl8 function in the endosome-lysosome sys-
tem.20–22 Thus far, these two Arls have not been associated
with human disease and the impact of their interaction
with TBC1D23 on brain development requires additional
studies.
To investigate the role of TBC1D23 in brain develop-
ment, we designed a zebrafish model of disease. A single
tbc1d23 ortholog (GenBank: NM_200487) encodes a pro-
tein with 77% identity with the human TBC1D23 amino
acid sequence. tbc1d23 transcript was detected as early as
the first hours post-fertilization (hpf) by RT-PCR, and by
in situ RNA hybridization tbc1d23 was primarily localized
in the head at 48 hpf (Figures 4A and 4B), suggesting a
role in brain development. To test whether knockdown
tbc1d23 in zebrafish replicates the human phenotype, we
knocked down tbc1d23 using a translation blocking
morpholino targeting the ATG start codon (tbc1d23-ATG
MO; 50-CTTCCCCTACAGCATCCGCCATTGC-30) and a
splice blocking morpholino targeting intron 4 to exon 5
(tbc1d23-splice MO; 50-GCAGTCTCTGCAAAAGGCAAT
ATGC-30). In contrast to scramble MO, both ATG and
splice MO-injected embryos (3 ng each) had reduced brain
and eye size and manifested curved tails at 48 hpf (more
severe in ATG MO embryos), and this phenotype was
partially rescued with injection of zebrafish tbc1d23
A D
B E
C
Figure 2. Splicing Mutations in TBC1D23 Cause Splicing Defects and Prevent Protein Synthesis
(A) RT-PCR of both TBC1D23 transcripts in different human tissues reveals that transcript 1 is predominantly expressed in the central
nervous system.
(B) RT-PCR from control (C), unaffected parents (F, father; M, mother), and affected subjects (1 and 2 from family II, 1 from family III).
Parents (carriers) showed splicing defect in the mutated allele, represented by the lack of exon 16 in both transcripts. Homozygous in-
dividuals manifested splicing defect in both alleles.
(C) Sequencing of PCR bands confirms the absence of exon 16 in both mutant transcripts.
(D) Western blot shows that TBC1D23 is absent in affected individuals and decreased in carriers compared to control.
(E) Representative immunofluorescence images of fibroblasts from control, carrier, and affected. In control and carrier fibroblasts,
TBC1D23 (rabbit 17002; Proteintech, 1:1,000) is located toward the trans-Golgi network as it overlaps with TGN46 (sheep; AbD Serotec;
1:1,000) and not with GM130 (mouse clone 35; BD; 1:1,000). In agreement with western blot results, cells from the affected individual
did not show signal except non-specific staining of the centrosome. The enlarged region shows details of TBC1D23 with the different
Golgi markers. Scale bars represent 10 mm.
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Figure 3. Trans-Golgi Location of TBC1D23 Depends on the C-Terminal Region and Is Regulated by Arl1 and Arl8
(A and B) HeLa cells were transfected usingMirus LT1 (Mirus LCC) with full-length GFP-tagged TBC1D23 (A) or with deletion constructs
outlined in the schematic (B). After 20 hr of the transfection, cells were fixed with 3% PFA (wt/vol) for 15 min, permeabilized with 0.1%
Triton X-100 (vol/vol) for 7 min, and then stained for TGN46 using a standard protocol. TBC1D23 was visualized using GFP. As illus-
trated, the region between amino acids 469 and 570 is responsible for the targeting of TBC1D23 to the trans-Golgi.
(C) HeLa cells were transfected using Oligofectamine (Life Technologies) with a specific library of siRNA duplexes targeting Arfs and Arls
(Dharmacon) for 72 hr (a subset of this library is shown). Cells were then fixed and stained as mentioned previously with antibodies
against TBC1D23, TGN46, and GM130. The depletion of Arl1 caused complete loss of TBC1D23 from the trans-Golgi, whereas knocking
down Arl8 increased TBC1D23 staining at the trans-Golgi. Depletion of ArfRP1, which controls Arl1 targeting to the Golgi, did not alter
TBC1D23 expression or localization. Western blot demonstrates efficient knockdown of targeted Rabs by siRNA duplexes and shows the
resulting expression of TBC1D23. In this case, HeLa cells were transfected with siRNA duplexes to Arl1, ArfRP1, and Arl8 or non-specific
control for 72 hr and transfected with expressing EGFP-tagged Arl1, ArfRP1, and Arl8 20 hr before collection for western blot. Antibodies
against EGFP (raised against full-length GFP in sheep) and Tubulin (mouse DM1A; Sigma-Aldrich) were used.
Scale bars represent 10 mm.
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A B
C
D
E
Figure 4. A Zebrafish Model Reproduces the Human Phenotype
(A) RT-PCR shows expression of zebrafish tbc1d23 at different developmental stages relative to control mobk13.23
(B) In situ RNA hybridization in AB embryos at 48 hr post-fertilization (hpf) with sense (negative control) and antisense (signal) probes
for tbc1d23. The expression of tbc1d23 occurs primarily in the head, pointing out its potential role in the development of cerebral
structures.
(C) Representative images of fishes injected with scramble, ATG, and splicing morpholinos (MO, all 3 ng) and rescued with zTbc1d23
mRNA (150–200 ng). Red arrows show reduced size of cerebellum and brainstem along with enlarged IV ventricle in ATG and splicing
MO fishes relative to scramble MO and rescued fishes.
(D) Quantification of morphometric parameters (9–11/condition). Reduced head and eye size and length of both ATG and splicing MO
fish was partially rescued with zTbc1d23 mRNA (n ¼ 10/condition).
(legend continued on next page)
The American Journal of Human Genetics 101, 441–450, September 7, 2017 447
mRNA (Figures 4C and 4D). These findings were corrobo-
rated in Tg(HuC:Kaede) transgenic zebrafish line, which ex-
presses the fluorescent protein Kaede in neurons. The ATG
MO injected Tg(HuC:Kaede) zebrafish showed reduced
signal in the neural axis and manifested altered
morphology of forebrain, brainstem, and cerebellum rela-
tive to scramble MO embryos (Figure 4E). Altogether,
tbc1d23 disruption in zebrafish replicates the human
phenotype by impairing brain growth and development.
This study enhances the genetic diagnosis and expands
the phenotypic spectrum of PCH. In contrast to most sub-
types, individuals with TBC1D23-associated PCH did not
show clinical neurological deterioration and MRI findings
did not worsen over time. None of the affected individ-
uals have died so far and the oldest are currently 16 years
old (I-IV-1 and III-IV-1). This distinctive clinical course is
therefore highly valuable for family counseling and prog-
nostication since most individuals with other PCH sub-
types show progressive worsening and typically succumb
during infancy or early childhood.2 TBC1D23 individuals
shared some neurological manifestations with other
forms of PCH, such as psychomotor impairment, micro-
cephaly, brainstem deficits, and ataxia.2 In addition to
severe volume loss of pons and cerebellum, TBC1D23
individuals manifested hypoplasia of cortex and of corpus
callosum as seen in other forms of PCH3 (Figure 1C). At
the systemic level, the most common findings in all
affected subjects were recurrent respiratory infections
and even sepsis (Table 1). This could relate to the essential
role of the brainstem to swallowing function and
handling respiratory secretions. However, it has been re-
ported that TBC1D23 may have inhibitory effects on
innate immunity and on LPS-induced cytokine release
in mice,24 and we cannot exclude the possibility that
loss of TBC1D23 could exacerbate the inflammatory
response against bacterial infections and lead to more se-
vere clinical manifestations. At baseline, affected individ-
uals did not show significant increase of inflammatory
markers and cytokine levels compared to control subjects
(Table S1). Thus, more studies are necessary to evaluate
the immune system of these individuals in order to deter-
mine their inflammatory response to infections.
Thus far, deleterious mutations in two TBC/RabGAPs
genes have been implicated in disorders of brain develop-
ment: TBC1D24 (MIM: 613577), which causes focal and
familial infantile myoclonic epilepsy,25–27 and TBCK
(MIM: 616899), which has been associated with severe
infantile syndromic encephalopathy.28–30 Like TBC1D23,
both TBC1D24 and TBCK are part of the unconventional
group of TBC/RabGAPs since they lack the Arg and/or
Gln fingers of the TBC domain. TBC1D24 regulates
neuronal migration and maturation by inactivating ADP
ribosylation factor (ARF) 6, a small GTPase involved in
vesicle trafficking.26 Whether ARF6 inactivation occurs
by direct or indirect induction of GTP hydrolysis is still un-
known. On the other hand, the target GTPase of TBCK has
not been yet identified. TBCK regulates cell growth and
proliferation by modulating transcription of several
constituents of the mTOR pathway.30 Structural and mo-
lecular modeling analyses of mutations in the TBC domain
suggests that TBCK may also have Rab GAP activity and
that the loss of GAP function is associated with disease.28
Our results point toward a Rab-independent trafficking
role of TBC1D23 that may be critical during hindbrain for-
mation, but not contributory to degeneration. Ivanova
et al.31 showed that vesicle trafficking in fibroblasts from
affected individuals lacking TBC1D23 is significantly
slower than control subjects. How this finding relates to
disruption of brain development needs to be elucidated.
Another PCH subtype that is not associated with neuro-
degeneration is PCH8.32 This condition is caused by muta-
tions in CHMP1A (MIM: 164010), a gene that regulates
proliferation of neural progenitor cells. CHMP1A has two
potential functions—as a charged multivesicular body pro-
tein and as a chromatin-modifying protein33,34—such that
it links cytoplasmic signals with chromatin modifications
to regulate proliferation of progenitor cells.32 Individuals
with mutations in CHMP1A manifest severe hypoplasia
of pons and cerebellum and cortical atrophy, and none
of them have shown progression of the clinical and radio-
logical findings, suggesting that this is a developmental
and not a degenerative disorder.32 Another non-degenera-
tive form of PCH not included in the current classification
is VLDLR-associated PCH (MIM: 192977). Along with apoE
receptor 2 (ApoER2), VLDLR serves as a Reelin receptor
to regulate microtubule function in migrating neurons.35
Individuals with damaging mutations in VLDLR manifest
non-progressive cerebellar hypoplasia with flattened
pons and cortical dysplasia.36,37 The majority of PCH sub-
types, however, are associated with disruption of protein
synthesis, for example by altering RNA processing (i.e.,
TSEN genes, RARS2, VRK1, TOE1, CLP1)6,8,38–40 or GTP-
dependent protein synthesis (i.e., AMPD2),41 functions
that are critical for brain development and considered
causative of degeneration when disrupted.2,7 In PCH,
how mutations in genes that regulate protein synthesis
cause neurodegeneration whereas genes involved in traf-
ficking and signaling impairs primarily brain develop-
ment, and why all these genes preferentially involve the
hindbrain are questions that remain unsolved. Whether
there are key molecular pathways involved in hindbrain
formation where these genes converge and lead to a pon-
tocerebellar phenotype is a matter that needs further
investigation.
(E) Transgenic line Huc:Kaede (CNS label) showed reduced signal and size of the neural axis of ATG MO compared to scramble MO,
which improved in the rescued fish. Drawings on the left illustrate the brain regions labeled in each transgenic fish.
All numerical values were expressed as mean5 SEM and statistical analysis was performed using two-tailed Student’s t test. *p < 0.05;
**p < 0.01, ***p < 0.001. Scale bars in (B) and (C) represent 200 mm, and in (E) represents 100 mm.
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Accession Numbers
The accession number for the TBC1D23 sequence reported in this
paper is Genbank: NM_001199198.2.
Supplemental Data
Supplemental Data include three figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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